Are there any notable changes in insider holdings or recent insider trading activity around the earnings release? | ACOG (Aug 06, 2025) | Candlesense
ACOG

Are there any notable changes in insider holdings or recent insider trading activity around the earnings release?

Answer

Based on the news release you provided (Alpha Cognition Inc.’s upcoming Q2 2025 earnings announcement on August 14, 2025), there is no information about insider holdings or insider trading activity included in the announcement itself. The press release only covers:

  • The date and timing of the earnings release (after the market close on 14 Aug 2025)
  • A follow‑up conference call for management to discuss the results

It does not mention any:

  • Changes in the number of shares owned by insiders (executives, directors, or large shareholders)
  • Recent purchases or sales of Alpha Cognition stock by insiders
  • Updates to insider ownership disclosed in a Form 4, Form 3, or Form 5 filing

How to Find Insider‑Activity Information Around the Earnings Release

Because the press release does not contain insider data, you’ll need to look elsewhere if you want to assess whether there have been notable changes in insider holdings or recent insider trades. Below are the most reliable sources and a quick step‑by‑step guide you can follow:

Source What to Look For How to Access
SEC Form 4 filings (or Form 3/5) Any purchase, sale, or grant of shares by insiders in the last 30 days (or since the last filing). Look for “non‑affiliated” and “affiliated” parties. • Go to the SEC’s EDGAR search portal → Company name “Alpha Cognition Inc.” → Filter by “Form 4”.
• Review the “Transaction” column for “Purchase” or “Sale” and the “Amount” column for the number of shares.
Beneficial Owner Reports (13‑D, 13‑G) Large beneficial owners (≥ 5 % of outstanding shares) who may have changed their stake. • Search EDGAR for “13‑D” or “13‑G” filings for ACOG.
NASDAQ/NYSE Insider Activity Tools Real‑time or delayed insider trade alerts, often with a “Recent Insider Trades” list. • Use the NASDAQ Insider page for ACOG (nasdaq.com/market-activity/insiders).
• Filter by date range (e.g., last 30 days).
Financial data platforms (e.g., Bloomberg, Refinitiv, FactSet, Yahoo! Finance) Consolidated insider‑trade summaries, change‑in‑ownership percentages, and “Insider Activity” dashboards. • Search for ticker ACOG → “Insider Transactions” or “Ownership”.
Company’s Investor Relations site Some companies post a “Insider Transactions” section or a link to the latest Form 4s. • Visit Alpha Cognition’s IR page → “SEC Filings” → Look for “Form 4”.

Quick Checklist to Spot “Notable” Changes

  1. Size of the trade – A single insider buying or selling a few thousand shares is routine; a trade involving > 5 % of the insider’s total holdings or > 10,000 shares (for a small‑cap company) may be material.
  2. Direction – A series of purchases by multiple executives could signal confidence, while a cluster of sales might indicate concerns or liquidity needs.
  3. Timing – Trades that occur within a few days before or after the earnings release (e.g., the week surrounding Aug 14) are especially relevant because they may be driven by expectations of the results.
  4. New grants or options exercised – Look for “Option Exercise” or “Stock Award” entries, which can temporarily inflate insider holdings.
  5. Change in percentage ownership – If an insider’s stake moves from, say, 1.2 % to 0.8 % (or vice‑versa), that shift is often highlighted in analyst commentary.

What This Means for Your Current Question

  • From the provided news release alone: No insider‑trading activity or changes in holdings are disclosed.
  • If you need a definitive answer: You will have to review the SEC filings (especially Form 4) and the other sources listed above for the period leading up to and following the August 14, 2025 earnings release.

If you conduct that search and still find no recent Form 4 filings or no significant changes in the 13‑D/13‑G beneficial‑owner reports, you can confidently conclude that there have been no notable insider‑trading events around the earnings release.

Sample Action Plan (If You Want to Verify Right Now)

  1. Open EDGAR: https://www.sec.gov/edgar/search/
  2. Enter “Alpha Cognition Inc.” → “Company name” or ticker “ACOG”.
  3. Select “Form 4” → Review filings dated July 1 2025 – August 20 2025 (covers the 2‑week window before and after the earnings call).
  4. Note any entries with “Purchase” or “Sale” and the number of shares.
  5. If none appear, you can state: “No insider transactions were reported in the relevant filing window.”

Bottom Line

  • The press release does not contain insider‑activity data.
  • To determine if there are notable changes, you must consult SEC filings (Form 4, 13‑D/13‑G) and reputable insider‑activity databases.
  • If those sources show no recent trades or changes, then the answer is that there have been no notable insider holdings changes or insider trading activity around the Q2 2025 earnings release.

Feel free to let me know if you’d like step‑by‑step instructions for pulling the Form 4s, or if you need help interpreting any specific filing you locate!

Other Questions About This News

Did Alpha Cognition disclose any new or updated milestones for its neuro‑degenerative disease pipeline (e.g., trial enrollment, data read‑outs, regulatory filings)? Did the company provide any forward guidance for Q3 and full-year 2025 earnings and revenue? Did the company provide any updates on risk factors, such as clinical trial delays, regulatory setbacks, or competition? How did the net loss per share compare to the prior quarter and what drivers contributed to any variance? How did the operating expenses, particularly R&D and SG&A, change versus the prior quarter and year‑over‑year? How does Alpha Cognition's valuation metrics (P/E, EV/EBITDA, price‑to‑cash‑flow) compare with peer companies in the neuro‑degenerative biotech space? What were the Q2 2025 revenue and earnings compared to the same quarter last year? How does the reported financial performance compare to analyst consensus estimates and the company's own guidance? Was there any discussion of upcoming catalysts that could affect the stock price (e.g., clinical trial results, FDA meetings, partnerships)? What is the current cash and cash‑equivalent balance and runway after accounting for recent expenses and capital needs? What is the impact of any recent grant, orphan drug, or other regulatory incentives on the financial outlook? What is the status of the company's collaborations, licensing deals, or partnership revenues? Were there any significant changes in the capital structure, such as share issuances, buybacks, or debt issuances during the quarter? What is the expected impact on the stock price after the earnings release and management commentary?